Evidence for this statement is provided by studies in which RvD2 (10 nM) treatment attenuated the response to virion spike 1 (S1) glycoprotein (an inflammation inducer of SARS-CoV-2) by reducing the release of selected chemokines and cytokines, including interleukin-8 (IL-8) and TNF-α, in macrophages from volunteers with and without cystic fibrosis [71]. The gene discussed is CXCL8; the disease is cystic fibrosis.